NICE updates methods ahead of 'widespread' use of biosimilars
This article was originally published in SRA
Executive Summary
UK health technology assessment body, the National Institute for Health and Care Excellence, has reviewed and updated its methods for providing guidance and advice on biosimilars in preparation for an expected increase in the number of such products coming onto the market1. Among other things, NICE says biosimilars could be subject either to a technology appraisal (guidance) or to a less prescriptive "evidence summary".
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.